Partnering Host Internship Host Institutions

Our partners

The SJSU SCILL consortium with the collaborative efforts academic centers, clinical institute and corporates prepare and train graduate-level students in stem cell research.
The Host Institutions offer a diverse array of research interests in basic stem cell biology, Regenerative and Translational Medicine with cutting-edge innovations and the state-of-the-art technology. Each institution works closely with the interns to provide them with experience and laboratory skills that will allow them to take advantage of career opportunities in stem cell research.


The institute was established in 2003 to build on Stanford’s leadership in stem cell science and to set the foundations for the creation of a new field of science: regenerative medicine. Under the direction of renowned stem cell researcher Dr. Irving Weissman, the institute is devoted to exploring the how stem cells are created, the mechanisms by which they are regulated and how they devolve into specialized cells.The ultimate goal is to translate this knowledge into dramatic new medical therapies for some of the world’s most serious and intractable afflictions. Finally, as part of Stanford School of Medicine, the institute is dedicated to training the next generation of stem cell researchers.

Learn More


Stem cell research at the University of California, Santa Cruz, focuses on the basic biological systems operating in the processes of self-renewal and differentiation of stem cells.
Stem cells hold great promise for curing or mitigating the effects of many diseases and injuries. But before a single clinical trial can commence, basic research must take place to uncover the pathways, mechanisms, and cellular effects of potential stem-cell-based cures. Basic research is also needed to overcome technological hurdles, such as how to ensure that stem cells work effectively when injected into a living organism. Investment in basic research of the kind done at the IBSC is an essential step toward stem-cell-based cures.

The Center for Biomolecular Science & Engineering administers the UCSC Institute for the Biology of Stem Cells

Learn More


Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four leading-edge neuroscientists and stem cell pioneers at The University of California, San Francisco. We are focused on the discovery and development of cell-based therapies to treat intractable neurological disease. Our initial aim is to generate therapeutic compositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. Based on nearly two decades of research, we believe that particular subpopulations of neurons have the unique ability to integrate and repair dysregulated neural circuits. Our talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs.

Learn More


Founded in 1988, The Parkinson’s Institute and Clinical Center (PI) is America’s only independent non-profit organization that provides basic and clinical research, clinical trials and a comprehensive movement disorder patient clinic for Parkinson’s disease (PD) and related neurological movement disorders, all under one roof. Our mission is to find the causes, provide first class patient care and discover a cure. Our unique freestanding organization supports a strong collaboration of translational medicine designed to more directly connect research to patient care – from the “bench to bedside”.

Learn More


Notable Labs is a personalized testing service for cancer patients that prioritizes combinations of FDA-approved treatments that can be immediately prescribed by a doctor without a clinical trial.

Learn More


Asterias Biotherapeutics is a development stage biotechnology company focusing on regenerative medicine. We are developing therapeutics based on two different platform technologies: cancer immunotherapy and pluripotent stem cells. Near term, we are leveraging these platforms to develop treatments to address significant unmet medical needs in oncology and neurology. These mature programs are focused on de-risked indications and are supported by robust proof-of-concept pre-clinical and clinical data.

Learn More


Cellerant Therapeutics is a privately held, clinical-stage biotechnology company with a portfolio of novel innate and adaptive immunotherapies for oncology and blood-related disorders, including cell-based and antibody therapeutics.  Cellerant's lead product, CLT-008, is a myeloid progenitor cell therapy currently in Phase 2 clinical development in patients with acute myeloid leukemia (AML).  The company also has a Cancer Stem Cell antibody (CSC) discovery program focused on therapies for AML, multiple myeloma and myelodysplastic syndrome. 

Learn More


BioTime is leading the next revolution in medicine – regenerative medicine. Regenerative medicine utilizes advances in stem cell biology, biomaterials, lab-generated cells and tissues, and biologics to engineer and provides healthy cells, tissues and organs to patients with chronic degenerative diseases. This revolution in medical science changes the focus from treating the symptoms of chronic and degenerative diseases by providing actual cures.

Learn More